Insights from Experiences on Antiplatelet Drugs in Stroke Prevention: A Review

Salvatore Santo Signorelli, Ingrid Platania, Salvatore Davide Tomasello, Marco Mangiafico, Giuliana Barcellona, Domenico Di Raimondo and Agostino Gaudio
Additional contact information
Salvatore Santo Signorelli: Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
Ingrid Platania: General Medicine Division, University Hospital G. Rodolico, 95123 Catania, Italy
Salvatore Davide Tomasello: Division of Hemodynamic and Interventional Cardiology, Hospital Cannizzaro, 95123 Catania, Italy
Marco Mangiafico: Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
Giuliana Barcellona: Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
Domenico Di Raimondo: Division of Internal Medicine and Stroke Care, Department of Promoting Health, Maternal-Infant, Excellence and Internal and Specialized Medicine (Promise) G. D’Alessandro, University of Palermo, 90127 Palermo, Italy
Agostino Gaudio: Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy

IJERPH, 2020, vol. 17, issue 16, 1-15

Abstract: Reduction of hazard risk of cerebral ischemic event (stroke, transient ischemic attack (TIA)) represents the hard point to be achieved from primary or secondary preventive strategy in the best clinical practice. However, results from clinical trials, recommendations, guidelines, systematic review, expert opinions, and meta-analysis debated on the optimal pharmacotherapy to achieve the objective. Aspirin and a number of antiplatelet agents, alone or in combination, have been considered from large trials focused on stroke prevention. The present review summarizes, discusses results from trials, and focuses on the benefits or disadvantages originating from antiplatelet drugs. Sections of the review were organized to show both benefits or consequences from antiplatelet pharmacotherapy. Conclusively, this review provides a potential synopsis on the most appropriate therapeutic approach for stroke prevention in clinical practice.

Keywords: prevention; stroke; aspirin; clopidogrel; cilostazol; dipyridamole; combined drug therapy (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/16/5840/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/16/5840/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:16:p:5840-:d:398121

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().